Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma. (Abstract 80)

Advertisement

Advertisement



Advertisement